1/2상모집 중

A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)

연구 개요

The purpose of this substudy is to assess the efficacy and safety of ifinatamab deruxtecan (I-DXd), given alone or with other treatments in participants with metastatic castration-resistant prostate cancer (mCRPC). The goals of this study are to learn about: * The safety of the study treatment and if people tolerate it. * A safe dose level of I-DXd that can be used with other treatments. * Participant levels of prostate specific antigen (PSA) during treatment.

스폰서: 리드: 머크(MSD)
적응증: Castration-Resistant Prostatic Cancer, Metastasis
중재: Docetaxel, Ifinatamab Deruxtecan, MK-5684, Abiraterone, Enzalutamide, Rescue Medication
목표 등록: 360명
시작일: 2025-07-03
완료(예정): 2031-04-01
등록번호: NCT06863272 · ClinicalTrials.gov ↗

BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.